WO2023235882A3 - Immunotherapy targeting egfr antigens - Google Patents
Immunotherapy targeting egfr antigens Download PDFInfo
- Publication number
- WO2023235882A3 WO2023235882A3 PCT/US2023/067889 US2023067889W WO2023235882A3 WO 2023235882 A3 WO2023235882 A3 WO 2023235882A3 US 2023067889 W US2023067889 W US 2023067889W WO 2023235882 A3 WO2023235882 A3 WO 2023235882A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egfr
- binding proteins
- antigens
- cell
- present disclosure
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 abstract 3
- 108091008324 binding proteins Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present disclosure provides compositions and methods for targeting EGFR antigens to, for example, treat or manage cancer. Provided compositions include binding proteins that are capable of binding to an EGFR antigen : HLA complex. Binding proteins include, for example, T cell receptors, fragments thereof, and chimeric antigen receptors. Also provided are polynucleotides and vectors encoding binding proteins. Disclosed polynucleotides and vectors can be introduced into an immune cell, such as a T cell, and used in immunotherapy in a subject having or at risk for a cancer associated with EGFR expression or activity. The present disclosure also provides immunogenic compositions comprising EGFR antigens, and related uses.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263348915P | 2022-06-03 | 2022-06-03 | |
| US63/348,915 | 2022-06-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023235882A2 WO2023235882A2 (en) | 2023-12-07 |
| WO2023235882A3 true WO2023235882A3 (en) | 2024-01-18 |
Family
ID=89025777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/067889 WO2023235882A2 (en) | 2022-06-03 | 2023-06-02 | Immunotherapy targeting egfr antigens |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023235882A2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140162320A1 (en) * | 2011-03-30 | 2014-06-12 | Masae Horii | Vector for foreign gene introduction, and method for producing vector in which foreign gene has been introduced |
| US20210213058A1 (en) * | 2018-03-12 | 2021-07-15 | The Children's Hospital Of Philadelphia | Methods and compositions for use of tumor self-antigens in adoptive immunotherapy |
| US20210380657A1 (en) * | 2018-10-25 | 2021-12-09 | The Council Of The Queensland Institute Of Medical Research | T-Cell Receptors and Uses Thereof |
| WO2022020319A2 (en) * | 2020-07-24 | 2022-01-27 | Tscan Therapeutics, Inc. | Binding proteins recognizing sars-cov-2 antigens and uses thereof |
-
2023
- 2023-06-02 WO PCT/US2023/067889 patent/WO2023235882A2/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140162320A1 (en) * | 2011-03-30 | 2014-06-12 | Masae Horii | Vector for foreign gene introduction, and method for producing vector in which foreign gene has been introduced |
| US20210213058A1 (en) * | 2018-03-12 | 2021-07-15 | The Children's Hospital Of Philadelphia | Methods and compositions for use of tumor self-antigens in adoptive immunotherapy |
| US20210380657A1 (en) * | 2018-10-25 | 2021-12-09 | The Council Of The Queensland Institute Of Medical Research | T-Cell Receptors and Uses Thereof |
| WO2022020319A2 (en) * | 2020-07-24 | 2022-01-27 | Tscan Therapeutics, Inc. | Binding proteins recognizing sars-cov-2 antigens and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023235882A2 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011225A (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers. | |
| MX2018011223A (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers. | |
| PH12018501933A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| EP4321529A3 (en) | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers | |
| CR20200515A (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
| JOP20200313A1 (en) | Dll3-cd3 bispecific antibodies | |
| CR20210033A (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
| CR20200408A (en) | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers | |
| PH12018501892A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| WO2020069184A3 (en) | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy | |
| ATE451388T1 (en) | TUMOR-ASSOCIATED PEPTIDES THAT BIND PROMISCUITIVELY TO CLASS II HUMAN LEUKOCYTE ANTIGEN (HLA) MOLECULES | |
| CR20210128A (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| ATE439375T1 (en) | IMMUNOGENIC T-HELPER EPITOPES OF HUMAN TUMOR ANTIGENS AND THEIR USE IN IMMUNOTHERAPEUTIC METHODS | |
| MX2018011220A (en) | Peptides and combination of peptides for use in immunotherapy against cancers. | |
| CR20210054A (en) | Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods | |
| WO2021094562A3 (en) | Antigenic peptides for prevention and treatment of b-cell malignancy | |
| MX2022007902A (en) | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy. | |
| PH12021550581A1 (en) | Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods | |
| CR20200607A (en) | Immunotherapy against melanoma and other cancers | |
| CR20210067A (en) | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
| CR20200632A (en) | A*03 restricted peptides for use in immunotherapy against cancers and related methods | |
| WO2021163562A3 (en) | Compositions and methods comprising splicing-derived antigens for treating cancer | |
| WO2022066965A3 (en) | Immunotherapy targeting sox2 antigens | |
| WO2023235882A3 (en) | Immunotherapy targeting egfr antigens | |
| WO2020127546A3 (en) | Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23816995 Country of ref document: EP Kind code of ref document: A2 |